Printer Friendly

COLUMBIA LABORATORIES SIGNS LETTER OF INTENT TO LICENSE AND SUPPLY REPLENS AND OTHER WOMEN'S OTC HEALTH CARE PRODUCTS

    COLUMBIA LABORATORIES SIGNS LETTER OF INTENT TO LICENSE AND SUPPLY
           REPLENS AND OTHER WOMEN'S OTC HEALTH CARE PRODUCTS
    HOLLYWOOD, Fla., Nov. 15 /PRNewswire/ -- Columbia Laboratories, Inc. (AMEX: COB) today announced that it has signed a non-binding letter of intent with Warner-Lambert Company (NYSE: WLA), with the intention of entering into a license and supply agreement under which Warner-Lambert would have exclusive rights to license Replens(R) in the United States and Canada.  The proposed agreement would provide Warner-Lambert with an option to negotiate exclusive licenses to other OTC women's health care products that Columbia is developing, based on its proprietary bioadhesive technology.  The two companies are now negotiating a definitive agreement.
    Upon completion of the definitive agreement, Warner-Lambert would become responsible for all marketing and sales of Replens, which is targeted to the many North American women who suffer from the problem of vaginal dryness.
    "We are exceptionally pleased by this pending agreement with Warner- Lambert," said Norman M. Meier, president and chief executive officer of Columbia.  "Having demonstrated in the marketplace during the past year that the product meets a very real need for women, we can now watch Replens reach its market potential with a company like Warner-Lambert."
    Financial details regarding the proposed agreement were not disclosed.
    Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company, established in 1987, dedicated primarily to developing and marketing women's health care products based on its patented bioadhesive drug delivery system.
    -0-              11/15/91
    /CONTACT:  Margaret Roell, chief financial officer of Columbia Laboratories, 305-964-6666, or Marcia A. Kean, executive vice president of Feinstein Partners, 617-577-8110, for Columbia Laboratories/
    (COB) (WLA) CO:  Columbia Laboratories, Inc.; Warner-Lambert Company ST:  Florida IN:  MTC SU:  LIC PS -- NY005 -- 1363 11/15/91 08:45 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 15, 1991
Words:292
Previous Article:MIDLAND FUNDING CORP. II $367 MILLION SUBORDINATED DEBT RATED
Next Article:MICHIGAN'S MAJOR UTILITIES ANNOUNCE IMPROVED PERFORMANCE OF FISH BARRIER NET AT LUDINGTON PLANT
Topics:


Related Articles
COLUMBIA LABORATORIES REPORTS NINE MONTHS AND THIRD QUARTER 1991 RESULTS
WARNER-LAMBERT COMPANY TO MARKET COLUMBIA LABORATORIES' REPLENS: AGREEMENT SIGNED FOR LICENSE AND SUPPLY ARRANGEMENT
COLUMBIA LABORATORIES REPORTS FISCAL 1991 RESULTS; OPERATING AND NET LOSSES DECREASE
COLUMBIA LABORATORIES EXPANDS WORLDWIDE MARKETING OF REPLENS(R) LOGOS AGREEMENT
TEVA PHARMACEUTICALS TO MARKET COLUMBIA LABORATORIES' WOMEN'S HEALTH CARE PRODUCTS IN ISRAEL
COLUMBIA LABORATORIES AND KODAK UNIT SIGN AGREEMENT TO EXPAND MARKETING OF REPLENS INTO JAPAN
COLUMBIA LABORATORIES REPORTS EXPECTED FIRST QUARTER 1993 FINANCIAL RESULTS
WARNER-LAMBERT, WELLCOME ENTER OTC JOINT VENTURE
ROBERTS PHARMACEUTICAL OBTAINS EXCLUSIVE CANADIAN RIGHTS TO REPLENS FROM COLUMBIA LABORATORIES
GENSIA LABORATORIES AND MICROBIX ANNOUNCE AGREEMENT FOR ACUTE CARDIOVASCULAR PRODUCT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters